Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders.
about
Use of Atypical Antipsychotics in the Treatment of Autistic DisorderMethylphenidate for core and ADHD-like symptoms in children aged 6 to 18 years with autism spectrum disorders (ASDs)Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)Psychiatric comorbidities in asperger syndrome and high functioning autism: diagnostic challengesLack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autismBroad and narrow personality traits as markers of one-time and repeated suicide attempts: a population-based studyExploring the manifestations of anxiety in children with autism spectrum disorders.Fluoxetine for Autistic Behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism.Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders.Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.Examination of aggression and self-injury in children with autism spectrum disorders and serious behavioral problemsThe Brief Obsessive-Compulsive Scale (BOCS): a self-report scale for OCD and obsessive-compulsive related disordersDeveloping drugs for core social and communication impairment in autism.Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trialCommentary on 'Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)'Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity.A genome scan for loci shared by autism spectrum disorder and language impairment.Pharmacologic treatment of repetitive behaviors in autism spectrum disorders: evidence of publication bias.Developmental disabilities modification of the Children's Global Assessment ScaleTolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial.Lurasidone for the Treatment of Irritability Associated with Autistic DisorderPharmacotherapy for the core symptoms in autistic disorder: current status of the researchEffects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptomsChildren with autism demonstrate circumscribed attention during passive viewing of complex social and nonsocial picture arrays.Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trialOutcome measures for clinical trials in fragile X syndrome.Family-Based Association Testing of OCD-associated SNPs of SLC1A1 in an autism sample.Predictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: a meta-analysisAn open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder.Predictors and moderators of parent training efficacy in a sample of children with autism spectrum disorders and serious behavioral problems.Autism spectrum and obsessive-compulsive disorders: OC behaviors, phenotypes and genetics.Functional neuroimaging of social and nonsocial cognitive control in autism.Children's Yale-Brown obsessive compulsive scale in autism spectrum disorder: component structure and correlates of symptom checklistMeasuring repetitive behaviors as a treatment endpoint in youth with autism spectrum disorder.Outcome measures in intervention trials for adults with autism spectrum disorders; a systematic review of assessments of core autism features and associated emotional and behavioural problems.Lurasidone for the treatment of irritability and anger in autism spectrum disorders.Overweight and obese status in children with autism spectrum disorder and disruptive behavior.Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder.Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome.
P2860
Q22241555-594321FC-60E3-4C13-9AED-466C60A33975Q24194593-C83974C0-881C-4464-BF3B-8C2CBE38BC87Q24200368-29136A9F-E85D-4C5A-9B5E-D31DF15C84BEQ24236316-F2D53606-F42C-4845-B813-CBB5D46C1C9FQ27498709-17638DD7-8211-47C9-97C3-42D54B47BF7CQ28247116-21181E87-C04B-4840-823B-07BB5B116F69Q33322939-783CA492-9964-47E3-9A58-9ED175A3B3CDQ33684282-C94D7A39-31B2-494A-9F0E-2D5F4257B266Q33794328-976EA149-3E00-4760-8FFB-4B0D8B25588FQ33819940-F064C051-66DD-476C-85DD-F62A7993B24BQ33858314-9BB54035-2C33-4799-805C-7AB6FF073CB6Q34417629-69F59FB5-2539-41C2-A1C0-B0BBD980CECCQ34456263-4D48BAB0-740E-4EE0-8CD5-DF4E96B4475FQ34822538-829CCBA7-9532-4569-82FA-7207F9424A9EQ35125984-77E050AA-D010-4E41-8370-22B12134752FQ35178499-A174FFED-0414-4B8C-B834-B92C6E7CE0F6Q35219299-2648E089-D3B8-4020-8FA2-0A73702A4F6BQ35606476-A66C319D-4798-4A98-8D3E-203B076D000AQ35923595-42CE150E-D245-4C9E-A1F5-F4E062F9097CQ35946655-17FC70F4-AF9D-4381-BB78-7F92866764C8Q35985482-A901B6F8-0E32-461A-BD3A-8EA50B0C19C4Q36674291-5C6C3D86-507F-4678-A6B4-09AB2EA84D72Q36784208-C4A17D5A-6C3E-4B9D-AA46-37F0DEB6CF5CQ36947682-E49B48F7-53EC-49AC-894E-669CC4F4B967Q37007554-A2CF4911-8228-4B4A-BE99-2A85D1BE4474Q37019876-13ED4D6F-E896-4A2B-9A4B-11CEC2650D21Q37199656-7C6D6B3D-D543-45FA-AB10-55FC13D65B11Q37208148-85D295F8-05D8-46C5-B8DE-6A94A0338C10Q37347743-141C13D0-7F77-49DF-BD43-C5E4099C93A7Q37409074-9E3AFD2B-9C58-416B-8EE8-5DAF318B40CAQ37547908-2FACF9EE-EBCD-41A7-92E2-8DDB909FA533Q37661412-D1E9570D-7DB4-40AD-AE88-F4641B783CEFQ37712054-29261E44-B8A6-4ABA-A7F2-E2FF6111DF0EQ37723279-250064AD-C0D8-46B1-B2FA-8875591131EAQ38164696-5367B936-5EEB-4054-99CB-1DE61A88D1DDQ38528316-ADD86E83-CC88-43DA-A09C-9DE7D06E92AFQ38689883-68551768-EA1C-4603-A7AB-ED114D6041DBQ38889139-F38442F9-51F8-44ED-9D82-399C10000415Q39347371-79F03C4D-9C20-4976-B009-D81F4C44CB9AQ39462489-434FDC35-B10F-4EBE-9014-7C033DC9037C
P2860
Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Children's Yale-Brown Obsessiv ...... asive developmental disorders.
@en
Children's Yale-Brown Obsessiv ...... asive developmental disorders.
@nl
type
label
Children's Yale-Brown Obsessiv ...... asive developmental disorders.
@en
Children's Yale-Brown Obsessiv ...... asive developmental disorders.
@nl
prefLabel
Children's Yale-Brown Obsessiv ...... asive developmental disorders.
@en
Children's Yale-Brown Obsessiv ...... asive developmental disorders.
@nl
P2093
P1476
Children's Yale-Brown Obsessiv ...... asive developmental disorders.
@en
P2093
Anastasia Dimitropoulos
Benedetto Vitiello
David J Posey
Elaine Tierney
James McGough
James T McCracken
Jaswinder Ghuman
Kathleen Koenig
Kristen S L Lam
L Eugene Arnold
P304
P356
10.1097/01.CHI.0000220854.79144.E7
P577
2006-09-01T00:00:00Z